viewPharmaxis Ltd

Pharmaxis reveals first sales of Aridol® in US following successful relaunch

Aridol is a lung function test designed to help doctors diagnose and manage asthma.

body imagine showing the human lungs
Shares last traded up 3.8% intra-day to 27 cents

Pharmaxis Ltd (ASX:PXS) has achieved the first sales of its asthma diagnostic test Aridol® in the US following the relaunch of the product.

This follows US FDA approval in August 2018 for its Sydney manufacturing facility to produce and supply Aridol to the US through its exclusive distribution partner Methapharm Inc.

Methapharm has extensive experience in the sales channels and specialist centres that conduct lung function testing.

READ: Pharmaxis receives FDA approval to produce Aridol for US market

Pharmaxis’s CEO Gary Phillips said, “Aridol was approved by the FDA in 2011 to identify bronchial hyperresponsiveness and commercialised by Pharmaxis in the US until its withdrawal from the market in 2013 as part of a corporate restructuring when we closed the facility used to manufacture Aridol for the US.

“Two years ago Pharmaxis partnered with Methapharm to re‐enter the US market and commenced the validation work required to have our remaining manufacturing facility approved by the FDA for Aridol. 

“Both Methapharm and Pharmaxis believe there remains a strong need in the US for objective tests to aid physicians in diagnosing asthma. It’s good to be back.”

Advancing partnership talks for LOXL2

Pharmaxis has a portfolio of drugs ranging from the pre-clinical phase through to the clinical phase and finally drugs in the commercial phase such as Aridol® and Bronchitol®.

Quick facts: Pharmaxis Ltd

Price: 0.195 AUD

Market: ASX
Market Cap: $76.96 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...



Pharmaxis hopeful of FDA approval for cystic fibrosis inhalation medicine...

Pharmaxis Ltd (ASX:PXS) chief executive officer Gary Phillips updates Proactive Investors on the FDA approval timeframe for the company’s Bronchitol inhalation medicine used to treat adult cystic fibrosis patients. The healthcare-focused company is confident it will meet information...

on 13/8/19

2 min read